142 related articles for article (PubMed ID: 3552537)
1. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study.
Jerums G; Murray RM; Seeman E; Cooper ME; Edgley S; Marwick K; Larkins RG; Martin TJ
Diabetes Res Clin Pract; 1987; 3(2):71-80. PubMed ID: 3552537
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
[TBL] [Abstract][Full Text] [Related]
4. Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
Minami N; Ikeda Y; Abe M
Tohoku J Exp Med; 1983 Dec; 141 Suppl():707-11. PubMed ID: 6440314
[TBL] [Abstract][Full Text] [Related]
5. [Diabetic retinopathy. Effects of gliclazide].
Lesobre B
Journ Annu Diabetol Hotel Dieu; 1983; ():275-80. PubMed ID: 6358618
[No Abstract] [Full Text] [Related]
6. [Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies].
Lesobre B
Sem Hop; 1983 Jun; 59(24):1827-33. PubMed ID: 6308816
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients.
Collier A; Watson HH; Patrick AW; Ludlam CA; Clarke BF
Diabete Metab; 1989; 15(6):420-5. PubMed ID: 2534084
[TBL] [Abstract][Full Text] [Related]
8. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas.
Akanuma Y; Kosaka K; Kanazawa Y; Kasuga M; Fukuda M; Aoki S
Diabetes Res Clin Pract; 1988 Jul; 5(2):81-90. PubMed ID: 3416710
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
Tsumura K
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
[TBL] [Abstract][Full Text] [Related]
10. Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
Donatelli M; Sinagra D; Russo V; Bucalo ML; Giardina E; Cerasola GA; Bompiani G
Pharmatherapeutica; 1985; 4(2):69-75. PubMed ID: 3903780
[TBL] [Abstract][Full Text] [Related]
11. [Value of gliclazide in the treatment of early diabetic retinopathy].
Cabral BV; Fernando R; Villegas-Cinco A; Icasas-Cabral E; Cinco L
Therapie; 1985; 40(4):231-3. PubMed ID: 4024018
[No Abstract] [Full Text] [Related]
12. The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
Saberi M; Ramazani Z; Rashidi H; Saberi A
Vasc Health Risk Manag; 2020; 16():241-248. PubMed ID: 32606720
[TBL] [Abstract][Full Text] [Related]
13. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
Harrower AD
Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
[TBL] [Abstract][Full Text] [Related]
14. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
[TBL] [Abstract][Full Text] [Related]
15. [A new therapeutic approach to diabetes. Long-term survey].
Charbonnel B
Sem Hop Ther; 1977 Nov; 53(9):460-5. PubMed ID: 341321
[No Abstract] [Full Text] [Related]
16. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
Harrower AD
J Diabetes Complications; 1994; 8(4):201-3. PubMed ID: 7833494
[TBL] [Abstract][Full Text] [Related]
17. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.
Satoh J; Takahashi K; Takizawa Y; Ishihara H; Hirai M; Katagiri H; Hinokio Y; Suzuki S; Tsuji I; Oka Y
Diabetes Res Clin Pract; 2005 Dec; 70(3):291-7. PubMed ID: 15949862
[TBL] [Abstract][Full Text] [Related]
18. Workshop VIII--Retinopathy, nephropathy, neuropathy, and tight control.
Lebovitz HE; Vinik AI
Am J Med; 1991 Feb; 90(2A):80S-84S. PubMed ID: 1994725
[No Abstract] [Full Text] [Related]
19. [The effects of prolonged treatment with gliclazide on the course of proteinuria and renal function in diabetic nephropathy].
Lagrue G; Kazandjian M; Gumpelson A; Riveline B
Therapie; 1978; 33(5):629-37. PubMed ID: 741422
[No Abstract] [Full Text] [Related]
20. [Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
Chan TK; Chan V; Teng CS; Yeung RT
Sem Hop; 1982 May; 58(19):1197-200. PubMed ID: 6285503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
